Fundamental and clinical studies of SY5555 in pediatrics

T. Yokota, H. Akita, Y. Sato, Y. Iwata, S. Iwata, K. Sunakawa

Research output: Contribution to journalArticle

Abstract

We assessed the in vitro antimicrobial activity and the clinical efficacy and safety of SY5555 in the field of pediatrics. The results obtained are summarized below. 1. In vitro antibacterial activities of SY5555 against 52 clinical isolates were compared with those of clavulanic acid/amoxicillin (CVA/AMPC), cefotiam (CTM), cefpodoxime (CPDX), cefaclor (CCL) and cefdinir (CFDN). Against Gram-positive bacteria, including Staphylococcus aureus, Streptococcus pneumoniae and Streptococcus pyogenes, SY5555 displayed antimicrobial activities superior or nearly equivalent to those of the reference agents used in the study. In cases of Gram-negative bacteria, the antimicrobial activity of SY5555 against Haemophilus influenzae was inferior to those of CPDX and CFDN. Against Klebsiella pneumoniae, the antimicrobial activity of SY5555 was less potent than that of CPDX. 2. Forty-seven children with infectious diseases were treated with SY5555 dry syrup (powder dissolved just before use). The clinical results were excellent in 24 and good in 16, with an efficacy rate of 85.1%. 3. Bacteriological screening identified 30 pathogenic organisms, and the eradication rate was 76.7%. 4. Side effects consisted of diarrhea in 12.5% (6 cases), loose stools in 4.2% (2 cases) and urticaria in 2.1% (1 case) of the patients. The only abnormal laboratory test value observed was an increase in eosinophil count in one child. 5. The palatability of SY5555 dry syrup was very good; it was very easily ingestible or easily ingestible by 32 of the 48 children. From the above results, SY5555 dry syrup appears to be a useful drug with a preferable safety profile in the treatment of pediatric patients with infectious diseases.

Original languageEnglish
Pages (from-to)92-102
Number of pages11
JournalJapanese Journal of Antibiotics
Volume48
Issue number1
Publication statusPublished - 1995
Externally publishedYes

Fingerprint

cefpodoxime
Pediatrics
cefdinir
Communicable Diseases
Cefotiam
Staphylococcal Pneumonia
Cefaclor
Safety
Amoxicillin-Potassium Clavulanate Combination
Clinical Studies
SUN 5555
Streptococcus pyogenes
Urticaria
Haemophilus influenzae
Klebsiella pneumoniae
Gram-Positive Bacteria
Streptococcus pneumoniae
Gram-Negative Bacteria
Eosinophils
Powders

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Yokota, T., Akita, H., Sato, Y., Iwata, Y., Iwata, S., & Sunakawa, K. (1995). Fundamental and clinical studies of SY5555 in pediatrics. Japanese Journal of Antibiotics, 48(1), 92-102.

Fundamental and clinical studies of SY5555 in pediatrics. / Yokota, T.; Akita, H.; Sato, Y.; Iwata, Y.; Iwata, S.; Sunakawa, K.

In: Japanese Journal of Antibiotics, Vol. 48, No. 1, 1995, p. 92-102.

Research output: Contribution to journalArticle

Yokota, T, Akita, H, Sato, Y, Iwata, Y, Iwata, S & Sunakawa, K 1995, 'Fundamental and clinical studies of SY5555 in pediatrics', Japanese Journal of Antibiotics, vol. 48, no. 1, pp. 92-102.
Yokota T, Akita H, Sato Y, Iwata Y, Iwata S, Sunakawa K. Fundamental and clinical studies of SY5555 in pediatrics. Japanese Journal of Antibiotics. 1995;48(1):92-102.
Yokota, T. ; Akita, H. ; Sato, Y. ; Iwata, Y. ; Iwata, S. ; Sunakawa, K. / Fundamental and clinical studies of SY5555 in pediatrics. In: Japanese Journal of Antibiotics. 1995 ; Vol. 48, No. 1. pp. 92-102.
@article{4ec3ad60dc734f6ea70ce9e5d7f8e03a,
title = "Fundamental and clinical studies of SY5555 in pediatrics",
abstract = "We assessed the in vitro antimicrobial activity and the clinical efficacy and safety of SY5555 in the field of pediatrics. The results obtained are summarized below. 1. In vitro antibacterial activities of SY5555 against 52 clinical isolates were compared with those of clavulanic acid/amoxicillin (CVA/AMPC), cefotiam (CTM), cefpodoxime (CPDX), cefaclor (CCL) and cefdinir (CFDN). Against Gram-positive bacteria, including Staphylococcus aureus, Streptococcus pneumoniae and Streptococcus pyogenes, SY5555 displayed antimicrobial activities superior or nearly equivalent to those of the reference agents used in the study. In cases of Gram-negative bacteria, the antimicrobial activity of SY5555 against Haemophilus influenzae was inferior to those of CPDX and CFDN. Against Klebsiella pneumoniae, the antimicrobial activity of SY5555 was less potent than that of CPDX. 2. Forty-seven children with infectious diseases were treated with SY5555 dry syrup (powder dissolved just before use). The clinical results were excellent in 24 and good in 16, with an efficacy rate of 85.1{\%}. 3. Bacteriological screening identified 30 pathogenic organisms, and the eradication rate was 76.7{\%}. 4. Side effects consisted of diarrhea in 12.5{\%} (6 cases), loose stools in 4.2{\%} (2 cases) and urticaria in 2.1{\%} (1 case) of the patients. The only abnormal laboratory test value observed was an increase in eosinophil count in one child. 5. The palatability of SY5555 dry syrup was very good; it was very easily ingestible or easily ingestible by 32 of the 48 children. From the above results, SY5555 dry syrup appears to be a useful drug with a preferable safety profile in the treatment of pediatric patients with infectious diseases.",
author = "T. Yokota and H. Akita and Y. Sato and Y. Iwata and S. Iwata and K. Sunakawa",
year = "1995",
language = "English",
volume = "48",
pages = "92--102",
journal = "The Journal of antibiotics. Ser. B",
issn = "0368-2781",
publisher = "Japan Antibiotics Research Association",
number = "1",

}

TY - JOUR

T1 - Fundamental and clinical studies of SY5555 in pediatrics

AU - Yokota, T.

AU - Akita, H.

AU - Sato, Y.

AU - Iwata, Y.

AU - Iwata, S.

AU - Sunakawa, K.

PY - 1995

Y1 - 1995

N2 - We assessed the in vitro antimicrobial activity and the clinical efficacy and safety of SY5555 in the field of pediatrics. The results obtained are summarized below. 1. In vitro antibacterial activities of SY5555 against 52 clinical isolates were compared with those of clavulanic acid/amoxicillin (CVA/AMPC), cefotiam (CTM), cefpodoxime (CPDX), cefaclor (CCL) and cefdinir (CFDN). Against Gram-positive bacteria, including Staphylococcus aureus, Streptococcus pneumoniae and Streptococcus pyogenes, SY5555 displayed antimicrobial activities superior or nearly equivalent to those of the reference agents used in the study. In cases of Gram-negative bacteria, the antimicrobial activity of SY5555 against Haemophilus influenzae was inferior to those of CPDX and CFDN. Against Klebsiella pneumoniae, the antimicrobial activity of SY5555 was less potent than that of CPDX. 2. Forty-seven children with infectious diseases were treated with SY5555 dry syrup (powder dissolved just before use). The clinical results were excellent in 24 and good in 16, with an efficacy rate of 85.1%. 3. Bacteriological screening identified 30 pathogenic organisms, and the eradication rate was 76.7%. 4. Side effects consisted of diarrhea in 12.5% (6 cases), loose stools in 4.2% (2 cases) and urticaria in 2.1% (1 case) of the patients. The only abnormal laboratory test value observed was an increase in eosinophil count in one child. 5. The palatability of SY5555 dry syrup was very good; it was very easily ingestible or easily ingestible by 32 of the 48 children. From the above results, SY5555 dry syrup appears to be a useful drug with a preferable safety profile in the treatment of pediatric patients with infectious diseases.

AB - We assessed the in vitro antimicrobial activity and the clinical efficacy and safety of SY5555 in the field of pediatrics. The results obtained are summarized below. 1. In vitro antibacterial activities of SY5555 against 52 clinical isolates were compared with those of clavulanic acid/amoxicillin (CVA/AMPC), cefotiam (CTM), cefpodoxime (CPDX), cefaclor (CCL) and cefdinir (CFDN). Against Gram-positive bacteria, including Staphylococcus aureus, Streptococcus pneumoniae and Streptococcus pyogenes, SY5555 displayed antimicrobial activities superior or nearly equivalent to those of the reference agents used in the study. In cases of Gram-negative bacteria, the antimicrobial activity of SY5555 against Haemophilus influenzae was inferior to those of CPDX and CFDN. Against Klebsiella pneumoniae, the antimicrobial activity of SY5555 was less potent than that of CPDX. 2. Forty-seven children with infectious diseases were treated with SY5555 dry syrup (powder dissolved just before use). The clinical results were excellent in 24 and good in 16, with an efficacy rate of 85.1%. 3. Bacteriological screening identified 30 pathogenic organisms, and the eradication rate was 76.7%. 4. Side effects consisted of diarrhea in 12.5% (6 cases), loose stools in 4.2% (2 cases) and urticaria in 2.1% (1 case) of the patients. The only abnormal laboratory test value observed was an increase in eosinophil count in one child. 5. The palatability of SY5555 dry syrup was very good; it was very easily ingestible or easily ingestible by 32 of the 48 children. From the above results, SY5555 dry syrup appears to be a useful drug with a preferable safety profile in the treatment of pediatric patients with infectious diseases.

UR - http://www.scopus.com/inward/record.url?scp=0028888842&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028888842&partnerID=8YFLogxK

M3 - Article

VL - 48

SP - 92

EP - 102

JO - The Journal of antibiotics. Ser. B

JF - The Journal of antibiotics. Ser. B

SN - 0368-2781

IS - 1

ER -